Medication cost of persons with dementia in primary care in Germany

Journal of Alzheimer's Disease

Volumn 42, Issue 3, 2014, Pages 949-958

  Michalowsky, Bernhard ^a   Eichler, Tilly ^a   Thyrian, Jochen René ^a   Hertel, Johannes ^a   Wucherer, Diana ^a   Laufs, Sebastian ^b   Fleßa, Steffen ^b   Hoffmann, Wolfgang ^a,b  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Dementia; drug substitution; drug therapy; economics; pharmaceutical economics

Indexed keywords

DONEPEZIL; GALANTAMINE; GENERIC DRUG; MEMANTINE; NOOTROPIC AGENT; RIVASTIGMINE; NEUROLEPTIC AGENT;

AGE; AGED; ARTICLE; BAYER ACTIVITIES OF DAILY LIVING SCALE; COGNITIVE DEFECT; COST BENEFIT ANALYSIS; CROSS-SECTIONAL STUDY; DAILY LIFE ACTIVITY; DEMENTIA; DEPRESSION; DISEASE SEVERITY; DRUG COST; FEMALE; GERMANY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; PRESCRIPTION; PRIMARY MEDICAL CARE; RATING SCALE; ECONOMICS; FOLLOW UP; HEALTH CARE COST; MENTAL HEALTH; NEUROPSYCHOLOGICAL TEST; PRIMARY HEALTH CARE; PSYCHOLOGY;

ACTIVITIES OF DAILY LIVING; AGED; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; DEMENTIA; FEMALE; FOLLOW-UP STUDIES; GERMANY; HEALTH CARE COSTS; HUMANS; MALE; MENTAL STATUS SCHEDULE; NEUROPSYCHOLOGICAL TESTS; PRIMARY HEALTH CARE;

EID: 84907150924     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140804     Document Type: Article

References (49)

1. World Health Organization (2012) Dementia: A public health priority.
2. Fendrich K, Hoffmann W (2007) More than just aging societies: The demographic change has an impact on actual numbers of patients. J Public Health 15, 345-351.
3. Hampel H, Prvulovic D, Teipel S, Jessen F, Luckhaus C, Frolich L, Riepe MW, Dodel R, Leyhe T, Bertram L, Hoffmann W, Faltraco F (2011) The future of Alzheimer's disease: The next 10 years. Prog Neurobiol 95, 718-728.
4. Lux G, Steinbach P,Wasem J,Weegen L,WalendzikA(2013) Demografie und Morbiditätsentwicklung. In Krankenhaus-Report 2013: Mengendynamik: Mehr Menge, mehr Nutzen Klauber J, Geraedts M, Friedrich J,Wasem J, eds. Schattauer GmbH, Stuttgart, pp. 69-82.
5. Statistisches Bundesamt, Gesundheit (2010) Krankheitskosten 2002, 2004, 2006 und 2008. 12, 1-45.
6. Statistische Ä mter des Bundes und der, Länder (2007) DemografischerWandel in Deutschland-Bevölkerungs-und Haushaltsentwicklung im Bund und in den Ländern. 2, 2-37.
7. Wimo A, Jonsson L, Winblad B (2006) An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord 21, 175-181.
8. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP (2013) The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement 9, 63-75.
9. Deutsche Gesellschaft für Psychiatrie PuND, Deutsche Gesellschaft für, Neurologie (2009) (DGN), S-3 Leitlinie "Demenzen", http://www.dgppn.de/fileadmin/user upload/medien/download/pdf/kurzversion-leitlinien/s3-leitlinie-dem enz-lf.pdf, Last updated February 17, 2010, Accessed on March 4, 2014
10. Köber R (2012) Therapeutisches Drug Monitoring von Antidementiva-Implementierung eines neuen HPLC/UVAnsatzes für das TDM aller Antidementiva in der medizinischen Routineanalytik und seine Relevanz für die Pharmakotherapie im gerontopsychiatrischen Klinikalltag, Verlag Dr, Kovac, Hamburg, pp.
11. Wimo A, Winblad B, Stoffler A, Wirth Y, Mobius HJ (2003) Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 21, 327-340.
12. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ (2003) Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348, 1333-1341.
13. Sano M,Wilcock GK, van BB, Kavanagh S (2003) The effects of galantamine treatment on caregiver time in Alzheimer's disease. Int J Geriatr Psychiatry 18, 942-950.
14. Kiencke P, Rychlik R, Grimm C, Daniel D (2010) [Cost of illness in Alzheimer's disease]. Med Klin (Munich) 105, 327-333.
15. Migliaccio-Walle K, Getsios D, Caro JJ, Ishak KJ, O'Brien JA, Papadopoulos G (2003) Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clin Ther 25, 1806-1825.
16. Fillit HM (2000) The pharmacoeconomics of Alzheimer's disease. Am J Manag Care 6, 1139-1144.
17. Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, Schwam EM, Shah S, Mastey V (2004) Economic evaluation of donepezil in moderate to severe Alzheimer disease. Neurology 63, 644-650.
18. Schwarzkopf L, Menn P, Kunz S, Holle R, Lauterberg J, Marx P, Mehlig H,Wunder S, Leidl R, Donath C, Graessel E (2011) Costs of care for dementia patients in community setting: An analysis for mild and moderate disease stage. Value Health 14, 827-835.
19. Hallauer J, Schons M, Smala A, Berger K (2000) Untersuchung von Krankheitskosten bei Patienten mit Alzheimer-Erkrankung in Deutschland. Gesundh ökon Qual manag 5, 73-79.
20. Leicht H, Heinrich S, Heider D, Bachmann C, Bickel H, van den BH, Fuchs A, Luppa M, Maier W, Mosch E, Pentzek M, Rieder-Heller SG, Tebarth F, Werle J, Weyerer S, Wiese B, Zimmermann T, Konig HH (2011) Net costs of dementia by disease stage. Acta Psychiatr Scand 124, 384-395.
21. Quentin W, Riedel-Heller SG, Luppa M, Rudolph A, Konig HH (2010) Cost-of-illness studies of dementia: A systematic review focusing on stage dependency of costs. Acta Psychiatr Scand 121, 243-259.
22. Ernst RL, HayJW, Fenn C, Tinklenberg J,Yesavage JA(1997) Cognitive function and the costs of Alzheimer disease. An exploratory study. Arch Neurol 54, 687-693.
23. Hauber AB, Gnanasakthy A, Snyder EH, Bala MV, Richter A, Mauskopf JA (2000) Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine. Pharmacoeconomics 17, 351-360.
24. Jonsson L (2004) Economic evidence in dementia: A review. Eur J Health Econ 5(Suppl 1), 30-35.
25. Wimo A, Ljunggren G, Winblad B (1997) Costs of dementia and dementia care: A review. Int J Geriatr Psychiatry 12, 841-856.
26. Leung GM, Yeung RY, Chi I, Chu LW(2003) The economics of Alzheimer disease. Dement Geriatr Cogn Disord 15, 34-43.
27. Schwarzkopf L, Menn P, Leidl R,Wunder S, Mehlig H, Marx P, Graessel E, Holle R (2012) Excess costs of dementia disorders and the role of age and gender-an analysis of German health and long-term care insurance claims data. BMC Health Serv Res 12, 165.
28. Leitliniengruppe Hessen (2013) Hausärztliche Leitline-Multimedikation, http://www.pmvforschungsgruppe.de/pdf/03 publikationen/multimedikation ll.pdf, 1-104, Last updated February 4, 2012, Accessed on March 4, 2014.
29. Lopez-Bastida J, Serrano-Aguilar P, Perestelo-Perez L, Oliva-Moreno J (2006) Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain. Neurology 67, 2186-2191.
30. Jonsson L, Eriksdotter JM, Kilander L, Soininen H, Hallikainen M,Waldemar G, Nygaard H, Andreasen N,Winblad B, Wimo A (2006) Determinants of costs of care for patients with Alzheimer's disease. Int J Geriatr Psychiatry 21, 449-459.
31. Leicht H, Konig HH, Stuhldreher N, Bachmann C, Bickel H, Fuchs A, Heser K, Jessen F, Kohler M, Luppa M, Mosch E, Pentzek M, Riedel-Heller S, Scherer M, Werle J, Weyerer S, Wiese B, Maier W (2013) Predictors of costs in dementia in a longitudinal perspective. PLos ONE 8, e70018.
32. Zhu CW, Leibman C, McLaughlin T, Zbrozek AS, Scarmeas N, Albert M, Brandt J, Blacker D, Sano M, Stern Y (2008) Patient dependence and longitudinal changes in costs of care in Alzheimer's disease. Dement Geriatr Cogn Disord 26, 416-423.
33. Zhu CW, Scarmeas N, Torgan R, Albert M, Brandt J, Blacker D, Sano M, Stern Y (2006) Clinical characteristics and longitudinal changes of informal cost of Alzheimer's disease in the community. J Am Geriatr Soc 54, 1596-1602.
34. Andersen CK, Lauridsen J, Andersen K, Kragh-Sorensen P (2003) Cost of dementia: Impact of disease progression estimated in longitudinal data. Scand J Public Health 31, 119-125.
35. Calabrese P, Kessler J (2000) Screening for cognitive impairment in dementia-the DemTect procedure. Eur Neuropsychopharmacol 10, 369.
36. Thyrian JR, Fiss T, Dreier A, Bowing G, Angelow A, Lueke S, Teipel S, Flessa S, Grabe HJ, Freyberger HJ, Hoffmann W (2012) Life-and person-centred help in Mecklenburg-Western Pomerania, Germany (DelpHi): Study protocol for a randomised controlled trial. Trials 13, 56.
37. Eichler T, Thyrian JR, Dreier A, Wucherer D, Kohler L, Fiss T, Bowing G, Michalowsky B, HoffmannW(2014) Dementia care management: Going newways in ambulant dementia care within a GP-based randomized controlled intervention trial. Int Psychogeriatr 26, 247-256.
38. Dreier A, Thyrian JR, Hoffmann W (2011) Dementia Care Manager in der ambulanten Demenzversorgung: Entwicklung einer innovativen Qualifizierung für Pflegefachkräfte. Pflege& Gesellschaft 16, 53-64.
39. Fiss T, Thyrian JR, Wucherer D, Assmann G, Kilimann I, Teipel SJ, Hoffmann W (2013) Medication management for people with dementia in primary care: Description of implementation in the DelpHi study. BMC Geriatr 13, 121.
40. Meyer J, Ostrzinski S, Fredrich D, Havemann C, Krafczyk J, Hoffmann W (2012) Efficient data management in a large-scale epidemiology research project. Comput Methods Programs Biomed 107, 425-435.
41. WIdO. (Wissenschaftliches Institut der AOK) (2013) GKV-Arzneimittelindex, http://www.wido.de/gkv-arzneimit telind.html.
42. Deutsches Institut für medizinische Dokumentation und Information (DIMDI) (2012) Klassifikation, Terminologien und Standards im Gesundheitswesen, http://www.dimdi.de/static/de/klassi/index.htm
43. Kessler J, Markowitsch HJ, Denzler P (1990) Mini-Mental-Status-Test (MMST) [German Version].
44. Hindmarch I, Lehfeld H, de JP, Erzigkeit H (1998) The Bayer Activities of Daily Living Scale (B-ADL). Dement Geriatr Cogn Disord 9(Suppl 2), 20-26.
45. Gauggel S, Birkner B (1999) Validity and reliability of a German version of the Geriatric Depression Scale (GDS). Zeitschrift für klinische psychologie-Forschung und Praxis 28, 18-27.
46. Desgagne A, Castilloux AM, Angers JF, LeLorier J (1998) The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics 13, 487-497.
47. StataCorp (2009) Stata Statistical Software: Release 11.
48. Schumbach K (2012) Memantin jetzt auch generisch, http://www.apotheke-adhoc.de/nachrichten/nachrichtdetail/memantin-jetzt-auch-generisch/, Last updated October 9, 2012, Accessed on March 4, 2014.
49. Wehling M, Burkhardt H (2010) Arzneitherapie für Ä ltere, Springer, Berlin.